

sustained exposure to agonists [36, 37]; however, different classes of cannabinoid agonists have different activities to induce receptor internalization even when they have similar agonist potencies [38], indicating that S-777469 may have a weak potency for CB₂ internalization. Although further research is required to examine this hypothesis, S-777469 might be suitable for long-term use.

In the present study, we demonstrated that S-777469 has an antipruritic effect on itch-associated scratching behavior triggered by several itch inducers via the suppression of itch signal transmission. From these findings, we propose that S-777469 may be part of an effective therapy for diseases associated with chronic itch, such as atopic dermatitis, without side effects on the CNS.

References

- Rothman S: Physiology of itching. *Physiol Rev* 1941;21:357–381.
- Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepletowski JC, et al: Itch: scratching more than the surface. *QJM* 2003;96:7–26.
- Handwerker HO, Forster C, Kirchhoff C: Discharge patterns of human C-fibers induced by itching and burning stimuli. *J Neurophysiol* 1991;66:307–315.
- Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE: Specific C-receptors for itch in human skin. *J Neurosci* 1997;17:8003–8008.
- Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjörk HE, Handwerker HO: Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. *J Neurophysiol* 2003;89:2441–2448.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 2002;54:161–202.
- Herkenham M, Lynn AB, Little MD, Ross Johnson M, Melvin LS, De Costa BR, et al: Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA* 1990;87:1932–1936.
- Pertwee RG: Evidence for the presence of CB₁ cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB₁ cannabinoid receptors. *Life Sci* 1999;65:597–605.
- Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I: Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. *Neuroscience* 2002;110:747–753.
- Klein TW, Newton CA, Friedman H: Cannabinoids and the immune system. *Pain Res Manag* 2001;6:95–101.
- Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al: HU-308: a specific agonist for CB₂, a peripheral cannabinoid receptor. *Proc Natl Acad Sci USA* 1999;96:14228–14233.
- Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al: Activation of CB₂ cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. *Proc Natl Acad Sci USA* 2003;100:10529–10533.
- Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, et al: New 1,8-naphthyridine and quinoline derivatives as CB₂ selective agonists. *Bioorg Med Chem Lett* 2007;17:6505–6510.
- Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papatjitis DP, Makriyannis A: Cannabimimetics: a novel class of CB₂ selective agonists with peripheral analgesic activity. *J Med Chem* 2007;50:6493–6500.
- Omura H, Kawai M, Shima A, Iwata Y, Ito F, Masuda T, et al: The SAR studies of novel CB₂ selective agonists, benzimidazolone derivatives. *Bioorg Med Chem Lett* 2008;18:3310–3314.
- Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al: Characterization of a cannabinoid CB₂ receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. *J Pharmacol Exp Ther* 2009;328:141–151.
- Dvorak M, Watkinson A, McGlone F, Rukwied R: Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. *Inflamm Res* 2003;52:238–245.
- Ständer S, Reinhardt HW, Luger TA: Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. *Hautarzt* 2006;57:801–807.
- Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, et al: Discovery of S-777469: an orally available CB₂ agonist as an antipruritic agent. *Bioorg Med Chem Lett* 2012;22:2803–2806.
- Nojima H, Carstens E: 5-Hydroxytryptamine (5-HT)₂ receptor involvement in acute 5-HT-evoked scratching but not in allergic pruritus induced by dinitrofluorobenzene in rats. *J Pharmacol Exp Ther* 2003;306:245–252.
- Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M: The neurobiology of itch. *Nat Rev Neurosci* 2006;7:535–547.
- Ständer S, Weisshaar E, Luger TA: Neurophysiological and neurochemical basis of modern pruritus treatment. *Exp Dermatol* 2008;7:161–169.
- Liu T, Ji RR: New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? *Pflugers Arch* 2013;465:671–685.
- Kuraishi Y, Nagasawa T, Hayashi K, Satoh M: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. *Eur J Pharmacol* 1995;275:229–233.
- Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, et al: Cannabinoid receptor CB₂ localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. *Pain* 2008;138:667–680.
- Sagar DR, Kelly S, Millns PJ, O'Shaughnessy CT, Kendall DA, Chapman V: Inhibitory effects of CB₁ and CB₂ receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. *Eur J Neurosci* 2005;22:371–379.
- Ständer S, Schmelz M, Metz D, Luger T, Rukwied R: Distribution of cannabinoid receptor 1 (CB₁) and 2 (CB₂) on sensory nerve fibers and adnexal structures in human skin. *J Dermatol Sci* 2005;38:177–188.
- Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG: Activation of cannabinoid CB₂ receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. *J Neurophysiol* 2004;92:3562–3574.
- Maekawa T, Nojima H, Kuraishi Y: Itch-associated responses of afferent nerve innervating the murine skin: different effects of histamine and serotonin in ICR and ddY mice. *Jpn J Pharmacol* 2000;84:462–466.

- 30 Andoh T, Katsube N, Maruyama M, Kuraishi Y: Involvement of leukotriene B₄ in substance P-induced itch-associated response in mice. *J Invest Dermatol* 2001;117:1621–1626.
- 31 Kajihara Y, Murakami M, Imagawa T, Otsuguro K, Ito S, Ohta T: Histamine potentiates acid-induced responses mediating transient receptor potential V1 in mouse primary sensory neurons. *Neuroscience* 2010;166:292–304.
- 32 Nicholson R, Small J, Dixon AK, Spanswick D, Lee K: Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. *Neurosci Lett* 2003;337:119–122.
- 33 Andoh T, Nagasawa T, Kuraishi Y: Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. *Brain Res Mol Brain Res* 1996;35:329–332.
- 34 Andoh T, Kuraishi Y: Expression of BLT1 leukotriene B₄ receptor on the dorsal root ganglion neurons in mice. *Brain Res Mol Brain Res* 2005;137:263–266.
- 35 Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al: CB₂ receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. *Eur J Neurosci* 2006;23:1530–1538.
- 36 Bouaboula M, Dussosoy D, Casellas P: Regulation of peripheral cannabinoid receptor CB₂ phosphorylation by the inverse agonist SR 144528. *J Biol Chem* 1999;274:20397–20405.
- 37 Grimsey NL, Goodfellow CE, Dragunow M, Glass M: Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. *Biochim Biophys Acta* 2011;1813:1554–1560.
- 38 Atwood BK, Wager-Miller J, Haskins C, Stricker A, Mackie K: Functional selectivity in CB₂ cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB₂ ligands. *Mol Pharmacol* 2012;81:250–263.

